Capricor Therapeutics
CAPR
32 hedge funds and large institutions have $12.5M invested in Capricor Therapeutics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 3 closing their positions.
218% more call options, than puts
Call options by funds: $528K | Put options by funds: $166K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
24% more capital invested
Capital invested by funds: $10.1M → $12.5M (+$2.4M)
7% more funds holding
Funds holding: 30 → 32 (+2)
0.75% more ownership
Funds ownership: 9.63% → 10.39% (+0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$345K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$293K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$135K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$78.6K |
| 5 |
BlackRock
New York
|
+$74.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$326K |
| 2 |
VF
Virtu Financial
New York
|
-$71K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$18.7K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$8.73K |
CAPR Hedge Fund Activity: Q2 2023 in Review
32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2023, worth a combined $12.5M — up 24% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CAPR positions and 3 closed out — a net gain of 3 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was LPL Financial, opening a new position worth an estimated $345K. The largest seller was Dimensional Fund Advisors, cutting an estimated $326K.
- 32 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2023, up from 30 in Q1 2023.
- Funds reported $12.5M of Capricor Therapeutics stock for Q2 2023, up 24% quarter-over-quarter.
- 6 funds opened new Capricor Therapeutics positions in Q2 2023 and 3 closed out, a net change of +3 holders.
- The largest Capricor Therapeutics buyer in Q2 2023 was LPL Financial, an estimated $345K added.
- The largest Capricor Therapeutics seller in Q2 2023 was Dimensional Fund Advisors, an estimated $326K sold.
Based on aggregated 13F filings for Q2 2023.